

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; le⦠read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
$3.11
Price-3.12%
-$0.10
$339.592m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$209.383m
+6.9%
1y CAGR-3.0%
3y CAGR-10.1%
5y CAGR-$1.87
+17.6%
1y CAGR+11.5%
3y CAGR+3.2%
5y CAGR$238.039m
$285.407m
Assets$47.368m
Liabilities$24.764m
Debt8.7%
-0.1x
Debt to EBITDA-$179.795m
+5.9%
1y CAGR-3.1%
3y CAGR-13.5%
5y CAGR